Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction

Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction

Item
http://www.wikidata.org/entity/Q27010907
Developments in managing severe chronic pain: role of oxycodone-naloxone extended releaseThe role of naloxegol in the management of opioid-induced bowel dysfunctionMethylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomesIntractable Constipation in the Elderly.Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.Gut Homeostasis, Microbial Dysbiosis, and Opioids.Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain.Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.In Search of the Ideal Promotility Agent: Optimal Use of Currently Available Promotility Agents for Nutrition Therapy of the Critically Ill Patient.Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy.Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotility.Investigational opioid antagonists for treating opioid-induced bowel dysfunction.[Bilateral hydronephrosis as a result of opioid-induced bowel spasm in a patient with an ileal conduit].Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model.Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
P2860

Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction

Item
http://www.wikidata.org/entity/Q27010907
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@ast
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@en
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@nl
type
label
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@ast
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@en
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@nl
prefLabel
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@ast
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@en
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P921
P932
P356
P1433
P1476
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
@en
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P921
P932